

# Kimmo Taari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2431457/publications.pdf>

Version: 2024-02-01

97  
papers

4,093  
citations

331670

21  
h-index

118850

62  
g-index

97  
all docs

97  
docs citations

97  
times ranked

5231  
citing authors

#	ARTICLE	IF	CITATIONS
1	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. <i>Lancet, The</i> , 2014, 384, 2027-2035.	13.7	1,261
2	Prostate-Cancer Mortality at 11 Years of Follow-up. <i>New England Journal of Medicine</i> , 2012, 366, 981-990.	27.0	1,105
3	A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. <i>European Urology</i> , 2019, 76, 43-51.	1.9	359
4	Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 913.	7.1	107
5	Optimal timing of post-biopsy MR imaging of the prostate. <i>Acta Radiologica</i> , 2001, 42, 70-73.	1.1	70
6	Prostatic MR imaging: Accuracy in differentiating cancer from other prostatic disorders. <i>Acta Radiologica</i> , 2001, 42, 348-354.	1.1	70
7	Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. <i>European Urology</i> , 2019, 76, 586-595.	1.9	68
8	Patients'™ perceptions of the negative effects following different prostate cancer treatments and the impact on psychological well-being: a nationwide survey. <i>British Journal of Cancer</i> , 2017, 116, 864-873.	6.4	56
9	Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Scandinavian Journal of Urology</i> , 2017, 51, 5-12.	1.0	41
10	Health-related quality of life in different states of breast cancer " comparing different instruments. <i>Acta Oncologica</i> , 2018, 57, 622-628.	1.8	41
11	Prostate cancer risk prediction using a polygenic risk score. <i>Scientific Reports</i> , 2020, 10, 17075.	3.3	39
12	Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. <i>European Urology Focus</i> , 2017, 3, 212-220.	3.1	37
13	&lt;p&gt;Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time&lt;/p&gt;. <i>Clinical Epidemiology</i> , 2019, Volume 11, 923-932.	3.0	37
14	A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. <i>European Journal of Epidemiology</i> , 2017, 32, 521-527.	5.7	36
15	Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening. <i>Clinical Cancer Research</i> , 2016, 22, 243-249.	7.0	35
16	Patient experiences at diagnosis and psychological well-being in prostate cancer: A Finnish national survey. <i>European Journal of Oncology Nursing</i> , 2015, 19, 220-229.	2.1	34
17	Magnetic resonance imaging of prostatic cancer: Does detection vary between high and low gleason score tumors?. <i>Prostate</i> , 2000, 43, 43-48.	2.3	33
18	Clonal heterogeneity influences drug responsiveness in renal cancer assessed by <i>ex vivo</i> drug testing of multiple patient-derived cancer cells. <i>International Journal of Cancer</i> , 2019, 144, 1356-1366.	5.1	29

#	ARTICLE	IF	CITATIONS
19	Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 66-76.	3.9	28
20	Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. <i>British Journal of Cancer</i> , 2014, 111, 1421-1431.	6.4	26
21	Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Journal of Urology</i> , 2017, 198, 50-57.	0.4	24
22	Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 917-924.	3.9	24
23	The association of financial difficulties and out-of-pocket payments with health-related quality of life among breast, prostate and colorectal cancer patients. <i>Acta Oncologica</i> , 2019, 58, 1062-1068.	1.8	22
24	Health-Related Quality of Life in the Finnish Trial of Screening for Prostate Cancer. <i>European Urology</i> , 2014, 65, 39-47.	1.9	21
25	Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial. <i>Prostate</i> , 2015, 75, 1394-1402.	2.3	19
26	Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. <i>British Journal of Cancer</i> , 2018, 118, 1248-1254.	6.4	18
27	The indirect costs of palliative care in end-stage cancer: A real-life longitudinal register- and questionnaire-based study. <i>Palliative Medicine</i> , 2018, 32, 493-499.	3.1	18
28	Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial. <i>PLoS ONE</i> , 2016, 11, e0153413.	2.5	18
29	Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era. <i>Scandinavian Journal of Urology</i> , 2018, 52, 419-426.	1.0	16
30	Partial nephrectomy with a combined CO <sub>2</sub> and Nd:YAG laser: Experimental study in pigs. <i>Lasers in Surgery and Medicine</i> , 1994, 14, 23-26.	2.1	14
31	5 $\alpha$ -Reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial. <i>International Journal of Cancer</i> , 2016, 138, 2820-2828.	5.1	14
32	Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Cancer Epidemiology</i> , 2016, 45, 1-5.	1.9	14
33	Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Scandinavian Journal of Urology</i> , 2016, 50, 413-419.	1.0	14
34	Morphological Effects of Photodynamic Therapy on Rabbit Bladder Using Photofrin II and Photosan Intravesically and Intravenously. <i>British Journal of Urology</i> , 1992, 70, 616-621.	0.1	13
35	Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study. <i>BJU International</i> , 2022, 130, 193-199.	2.5	13
36	Outcome of surgery for patients with renal cell carcinoma and tumour thrombus in the era of modern targeted therapy. <i>Scandinavian Journal of Urology</i> , 2016, 50, 380-386.	1.0	12

#	ARTICLE	IF	CITATIONS
37	Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer. <i>British Journal of Cancer</i> , 2016, 115, 1289-1295.	6.4	12
38	Health-related quality of life among prostate cancer patients: real-life situation at the beginning of treatment. <i>Scandinavian Journal of Urology</i> , 2017, 51, 13-19.	1.0	12
39	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. <i>PLoS ONE</i> , 2020, 15, e0234269.	2.5	12
40	Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial. <i>Cancer Causes and Control</i> , 2016, 27, 157-164.	1.8	11
41	Costs in different states of prostate cancer. <i>Acta Oncologica</i> , 2016, 55, 30-37.	1.8	11
42	Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial. <i>International Journal of Urology</i> , 2018, 25, 270-276.	1.0	11
43	Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 453-460.	3.9	11
44	USE OF PATIENT ASSESSED HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS IN PROSTATE CANCER RESEARCH: A SYSTEMATIC REVIEW OF THE LITERATURE 2002-2015. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 97-106.	0.5	10
45	Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study. <i>Cancer Imaging</i> , 2020, 20, 72.	2.8	10
46	Laparoscopic versus Open Nephrectomy for Renal Cell Carcinoma?. <i>Scandinavian Journal of Surgery</i> , 2004, 93, 132-136.	2.6	9
47	Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer. <i>BMC Cancer</i> , 2017, 17, 585.	2.6	9
48	Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort. <i>Scandinavian Journal of Urology</i> , 2018, 52, 321-327.	1.0	9
49	Holmium:YAG Laser for Urinary Stones. <i>Scandinavian Journal of Urology and Nephrology</i> , 1999, 33, 295-298.	1.4	8
50	The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia. <i>Prostate</i> , 2017, 77, 1029-1035.	2.3	8
51	A Four-kallikrein Panel and Î <sup>2</sup> -Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 561-567.	3.1	8
52	Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng/ml: long-term results from a randomized trial. <i>Scandinavian Journal of Urology</i> , 2021, 55, 348-353.	1.0	8
53	Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin. <i>European Urology</i> , 2015, 68, 1089-1097.	1.9	7
54	An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer. <i>Journal of Urology</i> , 2017, 198, 1333-1339.	0.4	7

#	ARTICLE	IF	CITATIONS
55	Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 373-378.	3.9	7
56	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC). <i>Clinical Cancer Research</i> , 2019, 25, 839-843.	7.0	7
57	Contact fibre Nd: YAG laser for partial nephrectomy: experimental study in pigs. <i>Urological Research</i> , 1993, 21, 301-304.	1.5	6
58	Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study. <i>European Urology</i> , 2016, 70, 499-505.	1.9	6
59	Allopurinol and the risk of prostate cancer in a Finnish population-based cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 483-490.	3.9	6
60	Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data. <i>PLoS ONE</i> , 2019, 14, e0224479.	2.5	6
61	Costs in Different States of Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 353-359.	1.1	6
62	Patients' education level and treatment modality for prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer. <i>European Journal of Cancer</i> , 2020, 130, 204-210.	2.8	6
63	Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate Cancer. <i>Cancer Causes and Control</i> , 2021, 32, 1299-1313.	1.8	6
64	Outcomes of Screening for Prostate Cancer Among Men Who Use Statins. <i>JAMA Oncology</i> , 2022, 8, 61.	7.1	6
65	Renal Function after Partial Nephrectomy with the Nd:YAG Laser Experimental Study in Piglets. <i>British Journal of Urology</i> , 1991, 68, 459-462.	0.1	5
66	Efficacy and Complications of the ND:YAG Laser in Partial Nephrectomy: Experimental Study in Piglets. <i>Scandinavian Journal of Urology and Nephrology</i> , 1991, 25, 303-306.	1.4	5
67	Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. <i>European Urology Focus</i> , 2018, 4, 851-857.	3.1	5
68	Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer. <i>Cancer Causes and Control</i> , 2019, 30, 877-888.	1.8	5
69	Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data. <i>European Journal of Cancer</i> , 2018, 93, 108-118.	2.8	4
70	Renal Tumor Invasion Depth and Diameter are the Two Most Accurate Anatomical Features Regarding the Choice of Radical Versus Partial Nephrectomy. <i>Scandinavian Journal of Surgery</i> , 2018, 107, 54-61.	2.6	4
71	Health-Related Quality of Life and Survival in Prostate Cancer Patients in a Real-World Setting. <i>Urologia Internationalis</i> , 2020, 104, 939-947.	1.3	4
72	Long-term health-related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 5643-5654.	2.8	4

#	ARTICLE	IF	CITATIONS
73	Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). <i>Cancer</i> , 2021, 127, 188-192.	4.1	4
74	Shoulder pain due to rupture of a calyceal diverticulum as an acute sign of prostatic hyperplasia. <i>British Journal of Urology</i> , 1994, 73, 458-459.	0.1	3
75	Outcomes of Prostate Cancer Screening by 5 $\alpha$ -Reductase Inhibitor Use. <i>Journal of Urology</i> , 2017, 198, 305-309.	0.4	3
76	Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer. <i>International Journal of Cancer</i> , 2019, 145, 632-638.	5.1	3
77	Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma. <i>Scandinavian Journal of Urology</i> , 2020, 54, 413-419.	1.0	3
78	Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation. <i>Cancers</i> , 2021, 13, 435.	3.7	3
79	Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 982-989.	2.5	3
80	Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. <i>International Journal of Cancer</i> , 2021, 149, 307-315.	5.1	3
81	Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level. <i>Cancers</i> , 2022, 14, 2920.	3.7	3
82	Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men. <i>Scientific Reports</i> , 2018, 8, 10308.	3.3	2
83	Parenchyma-conserving surgery for renal cell carcinoma. <i>Annales Chirurgiae Et Gynaecologiae Supplementum</i> , 1993, 206, 54-8.	0.0	2
84	Radioiodinated estramustine phosphate and estramustine binding protein Antibody accumulate in the prostate of a mouse. , 1997, 32, 1-8.		1
85	Evolving Clinical Picture of Renal Cell Carcinoma: A Population-Based Study from Helsinki. <i>Urologia Internationalis</i> , 2019, 102, 390-398.	1.3	1
86	Hand-assisted laparoscopic versus open partial nephrectomy in patients with T1 renal tumor: Comparative perioperative, functional and oncological outcome. <i>Scandinavian Journal of Urology</i> , 2015, 49, 446-452.	1.0	1
87	Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer. <i>British Journal of Cancer</i> , 2022, , .	6.4	1
88	Effect of alcohol on bladder function: A uroflowmetric and cystometric study. <i>Neurourology and Urodynamics</i> , 1990, 9, 591-594.	1.5	0
89	Outcomes of prostate cancer screening among men using antidiabetic medication. <i>Scientific Reports</i> , 2021, 11, 7363.	3.3	0
90	Title is missing!. , 2019, 14, e0224479.		0

#	ARTICLE	IF	CITATIONS
91	Title is missing!. , 2019, 14, e0224479.		0
92	Title is missing!. , 2019, 14, e0224479.		0
93	Title is missing!. , 2019, 14, e0224479.		0
94	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
95	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
96	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
97	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0